Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
The Genomic Landscapes of Human Breast and Colorectal Cancers
Laura D. Wood,1*D. Williams Parsons,1*Siân Jones,1*Jimmy Lin,1*Tobias Sjöblom,1*Rebecca J. Leary,1Dong Shen,1Simina M. Boca,1,2Thomas Barber,1Janine Ptak,1Natalie Silliman,1Steve Szabo,1Zoltan Dezso,3Vadim Ustyanksky,3Tatiana Nikolskaya,3,4Yuri Nikolsky,3Rachel Karchin,5Paul A. Wilson,5Joshua S. Kaminker,6Zemin Zhang,6Randal Croshaw,7Joseph Willis,8Dawn Dawson,8Michail Shipitsin,9James K. V. Willson,10Saraswati Sukumar,11Kornelia Polyak,9Ben Ho Park,11Charit L. Pethiyagoda,12P. V. Krishna Pant,12Dennis G. Ballinger,12Andrew B. Sparks,12James Hartigan,13Douglas R. Smith,13Erick Suh,13Nickolas Papadopoulos,1Phillip Buckhaults,7Sanford D. Markowitz,14Giovanni Parmigiani,1||Kenneth W. Kinzler,1||Victor E. Velculescu,1||Bert Vogelstein1||
Human cancer is caused by the accumulation of mutations in oncogenesand tumor suppressor genes. To catalog the genetic changes thatoccur during tumorigenesis, we isolated DNA from 11 breast and11 colorectal tumors and determined the sequences of the genesin the Reference Sequence database in these samples. Based onanalysis of exons representing 20,857 transcripts from 18,191genes, we conclude that the genomic landscapes of breast andcolorectal cancers are composed of a handful of commonly mutatedgene "mountains" and a much larger number of gene "hills" thatare mutated at low frequency. We describe statistical and bioinformatictools that may help identify mutations with a role in tumorigenesis.These results have implications for understanding the natureand heterogeneity of human cancers and for using personal genomicsfor tumor diagnosis and therapy.
1 The Ludwig Center for Cancer Genetics and Therapeutics and The Howard Hughes Medical Institute at The Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA. 2 Department of Biostatistics, Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. 3 GeneGo, St. Joseph, MI 49085, USA. 4 Vavilov Institute of General Genetics, Moscow, Russia. 5 Department of Biomedical Engineering, Institute of Computational Medicine, Johns Hopkins University, Baltimore, MD 21218, USA. 6 Department of Bioinformatics, Genentech, San Francisco, CA 94080, USA. 7 Department of Pathology and Microbiology, The Center for Colon Cancer Research, and The South Carolina Cancer Center, Division of Basic Research, The University of South Carolina, School of Medicine, Columbia, SC 29229, USA. 8 Department of Pathology and Ireland Cancer Center, Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH 44106, USA. 9 Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. 10 Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA. 11 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA. 12 Perlegen Sciences, Mountain View, CA 94043, USA. 13 Agencourt Bioscience Corporation, Beverly, MA 01915, USA. 14 Department of Medicine and Ireland Cancer Center, Case Western Reserve University and University Hospitals of Cleveland, and Howard Hughes Medical Institute, Cleveland, OH 44106, USA.
* These authors contributed equally to this work.
Present address: Department of Genetics and Pathology, UppsalaUniversity, SE-751 85 Uppsala, Sweden.
Present address: Lilly Research Labs, Eli Lilly and Company,Indianapolis, IN 42685, USA.
Present address: Complete Genomics, Sunnyvale, CA 94085, USA.
|| To whom correspondence should be addressed. E-mail: gp{at}jhu.edu (G.P.); kinzlke{at}jhmi.edu (K.W.K.); velculescu{at}jhmi.edu (V.E.V.); vogelbe{at}welch.jhu.edu (B.V.)
The editors suggest the following Related Resources on Science sites:
In Science Magazine
PERSPECTIVES
Jeffrey M. Trent and Jeffrey W. Touchman (16 November 2007) Science318 (5853), 1079.
[DOI: 10.1126/science.1151428] |Summary »|Full Text »|PDF »
In Science Signaling
EDITORS' CHOICE
Paula A. Kiberstis (20 November 2007) Sci. STKE2007 (413), tw428.
[DOI: 10.1126/stke.4132007tw428] |Abstract »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The DNA repair gene APE1 T1349G polymorphism and cancer risk: a meta-analysis of 27 case-control studies.
D. Gu, M. Wang, M. Wang, Z. Zhang, and J. Chen (2009)
Mutagenesis
24, 507-512
|Abstract »|Full Text »|PDF »
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.
M. L. Sos, S. Fischer, R. Ullrich, M. Peifer, J. M. Heuckmann, M. Koker, S. Heynck, I. Stuckrath, J. Weiss, F. Fischer, et al. (2009)
PNAS
106, 18351-18356
|Abstract »|Full Text »|PDF »
A Modified Sleeping Beauty Transposon System That Can Be Used to Model a Wide Variety of Human Cancers in Mice.
A. J. Dupuy, L. M. Rogers, J. Kim, K. Nannapaneni, T. K. Starr, P. Liu, D. A. Largaespada, T. E. Scheetz, N. A. Jenkins, and N. G. Copeland (2009)
Cancer Res.
69, 8150-8156
|Abstract »|Full Text »|PDF »
Discovery and validation of colonic tumor-associated proteins via metabolic labeling and stable isotopic dilution.
E. L. Huttlin, X. Chen, G. A. Barrett-Wilt, A. D. Hegeman, R. B. Halberg, A. C. Harms, M. A. Newton, W. F. Dove, and M. R. Sussman (2009)
PNAS
106, 17235-17240
|Abstract »|Full Text »|PDF »
Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
A. Cerrato, V. De Falco, and M. Santoro (2009)
J. Mol. Endocrinol.
43, 143-155
|Abstract »|Full Text »|PDF »
PCR-free method detects high frequency of genomic instability in prostate cancer.
N. M. Makridakis, T. Phipps, S. Srivastav, and J. K. V. Reichardt (2009)
Nucleic Acids Res.
|Abstract »|Full Text »|PDF »
Bioinformatics construction of the human cell surfaceome.
J. P. C. da Cunha, P. A. F. Galante, J. E. de Souza, R. F. de Souza, P. M. Carvalho, D. T. Ohara, R. P. Moura, S. M. Oba-Shinja, S. K. N. Marie, W. A. Silva Jr, et al. (2009)
PNAS
106, 16752-16757
|Abstract »|Full Text »|PDF »
Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential.
E. R. Andrechek, R. D. Cardiff, J. T. Chang, M. L. Gatza, C. R. Acharya, A. Potti, and J. R. Nevins (2009)
PNAS
106, 16387-16392
|Abstract »|Full Text »|PDF »
Identification of Novel Gene Amplifications in Breast Cancer and Coexistence of Gene Amplification with an Activating Mutation of PIK3CA.
M. Kadota, M. Sato, B. Duncan, A. Ooshima, H. H. Yang, N. Diaz-Meyer, S. Gere, S.-I. Kageyama, J. Fukuoka, T. Nagata, et al. (2009)
Cancer Res.
69, 7357-7365
|Abstract »|Full Text »|PDF »
A Risk Variant in an miR-125b Binding Site in BMPR1B Is Associated with Breast Cancer Pathogenesis.
P. Saetrom, J. Biesinger, S. M. Li, D. Smith, L. F. Thomas, K. Majzoub, G. E. Rivas, J. Alluin, J. J. Rossi, T. G. Krontiris, et al. (2009)
Cancer Res.
69, 7459-7465
|Abstract »|Full Text »|PDF »
Mechanisms of bone metastases of breast cancer.
L. J Suva, R. J Griffin, and I. Makhoul (2009)
Endocr. Relat. Cancer
16, 703-713
|Abstract »|Full Text »|PDF »
Saturation Density of Skin Fibroblasts as a Quantitative Screen for Human Cancer Susceptibility.
Expression and localisation of insulin receptor substrate 2 in normal intestine and colorectal tumours. Regulation by intestine-specific transcription factor CDX2.
S Modica, A Morgano, L Salvatore, M Petruzzelli, M-T Vanier, R Valanzano, D L Esposito, G Palasciano, I Duluc, J-N Freund, et al. (2009)
Gut
58, 1250-1259
|Abstract »|Full Text »|PDF »
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.
B. Neyns, J. Sadones, E. Joosens, F. Bouttens, L. Verbeke, J.-F. Baurain, L. D'Hondt, T. Strauven, C. Chaskis, P. In't Veld, et al. (2009)
Ann. Onc.
20, 1596-1603
|Abstract »|Full Text »|PDF »
Identification of rare cancer driver mutations by network reconstruction.
Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab.
D. Faratian, A. Goltsov, G. Lebedeva, A. Sorokin, S. Moodie, P. Mullen, C. Kay, I. H. Um, S. Langdon, I. Goryanin, et al. (2009)
Cancer Res.
69, 6713-6720
|Abstract »|Full Text »|PDF »
Cancer-Specific High-Throughput Annotation of Somatic Mutations: Computational Prediction of Driver Missense Mutations.
H. Carter, S. Chen, L. Isik, S. Tyekucheva, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, and R. Karchin (2009)
Cancer Res.
69, 6660-6667
|Abstract »|Full Text »|PDF »
Copy number variation has little impact on bead-array-based measures of DNA methylation.
E. A. Houseman, B. C. Christensen, M. R. Karagas, M. R. Wrensch, H. H. Nelson, J. L. Wiemels, S. Zheng, J. K. Wiencke, K. T. Kelsey, and C. J. Marsit (2009)
Bioinformatics
25, 1999-2005
|Abstract »|Full Text »|PDF »
Adenomatous Polyposis Coli and Asef Function Downstream of Hepatocyte Growth Factor and Phosphatidylinositol 3-Kinase.
Y. Kawasaki, S. Tsuji, M. Sagara, K. Echizen, Y. Shibata, and T. Akiyama (2009)
J. Biol. Chem.
284, 22436-22443
|Abstract »|Full Text »|PDF »
Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers.
K. Guda, H. Moinova, J. He, O. Jamison, L. Ravi, L. Natale, J. Lutterbaugh, E. Lawrence, S. Lewis, J. K. V. Willson, et al. (2009)
PNAS
106, 12921-12925
|Abstract »|Full Text »|PDF »
High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications.
S. Ocak, M. L. Sos, R. K. Thomas, and P. P. Massion (2009)
Eur. Respir. J.
34, 489-506
|Abstract »|Full Text »|PDF »
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment.
Y. Lee, S. L. Auh, Y. Wang, B. Burnette, Y. Wang, Y. Meng, M. Beckett, R. Sharma, R. Chin, T. Tu, et al. (2009)
Blood
114, 589-595
|Abstract »|Full Text »|PDF »
Infrequent Detection of Germline Allele-Specific Expression of TGFBR1 in Lymphoblasts and Tissues of Colon Cancer Patients.
K. Guda, L. Natale, J. Lutterbaugh, G. L. Wiesner, S. Lewis, S. M. Tanner, J. Tomsic, L. Valle, A. de la Chapelle, R. C. Elston, et al. (2009)
Cancer Res.
69, 4959-4961
|Abstract »|Full Text »|PDF »
Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA, and AKT1.
J. C. Ricarte-Filho, M. Ryder, D. A. Chitale, M. Rivera, A. Heguy, M. Ladanyi, M. Janakiraman, D. Solit, J. A. Knauf, R. M. Tuttle, et al. (2009)
Cancer Res.
69, 4885-4893
|Abstract »|Full Text »|PDF »
Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen.
V. L. Martins, J. J. Vyas, M. Chen, K. Purdie, C. A. Mein, A. P. South, A. Storey, J. A. McGrath, and E. A. O'Toole (2009)
J. Cell Sci.
122, 1788-1799
|Abstract »|Full Text »|PDF »
Methylation of TFPI2 in Stool DNA: A Potential Novel Biomarker for the Detection of Colorectal Cancer.
S. C. Glockner, M. Dhir, J. M. Yi, K. E. McGarvey, L. Van Neste, J. Louwagie, T. A. Chan, W. Kleeberger, A. P. de Bruine, K. M. Smits, et al. (2009)
Cancer Res.
69, 4691-4699
|Abstract »|Full Text »|PDF »
Genetic Inactivation of ADAMTS15 Metalloprotease in Human Colorectal Cancer.
C. G. Viloria, A. J. Obaya, A. Moncada-Pazos, M. Llamazares, A. Astudillo, G. Capella, S. Cal, and C. Lopez-Otin (2009)
Cancer Res.
69, 4926-4934
|Abstract »|Full Text »|PDF »
Mutation-associated fusion cancer genes in solid tumors.
Epithelial-to-Mesenchymal Transition and Resistance to Ingenol 3-Angelate, a Novel Protein Kinase C Modulator, in Colon Cancer Cells.
A. Ghoul, M. Serova, L. Astorgues-Xerri, I. Bieche, G. Bousquet, M. Varna, M. Vidaud, E. Phillips, S. Weill, K. A. Benhadji, et al. (2009)
Cancer Res.
69, 4260-4269
|Abstract »|Full Text »|PDF »
Integrative Analysis of Genome-Wide RNA Interference Screens.
J. D. Berndt, T. L. Biechele, R. T. Moon, and M. B. Major (2009)
Science Signaling
2, pt4
|Abstract »|Full Text »|PDF »
Global Histone Modifications in Breast Cancer Correlate with Tumor Phenotypes, Prognostic Factors, and Patient Outcome.
S. E. Elsheikh, A. R. Green, E. A. Rakha, D. G. Powe, R. A. Ahmed, H. M. Collins, D. Soria, J. M. Garibaldi, C. E. Paish, A. A. Ammar, et al. (2009)
Cancer Res.
69, 3802-3809
|Abstract »|Full Text »|PDF »
Analysis of DNA Copy Number Alterations in Ovarian Serous Tumors Identifies New Molecular Genetic Changes in Low-Grade and High-Grade Carcinomas.
K.-T. Kuo, B. Guan, Y. Feng, T.-L. Mao, X. Chen, N. Jinawath, Y. Wang, R. J. Kurman, I.-M. Shih, and T.-L. Wang (2009)
Cancer Res.
69, 4036-4042
|Abstract »|Full Text »|PDF »
Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer.
A. Blackford, G. Parmigiani, T. W. Kensler, C. Wolfgang, S. Jones, X. Zhang, D. W. Parsons, J. C.-H. Lin, R. J. Leary, J. R. Eshleman, et al. (2009)
Cancer Res.
69, 3681-3688
|Abstract »|Full Text »|PDF »
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene.
S. Jones, R. H. Hruban, M. Kamiyama, M. Borges, X. Zhang, D. W. Parsons, J. C.-H. Lin, E. Palmisano, K. Brune, E. M. Jaffee, et al. (2009)
Science
324, 217
|Abstract »|Full Text »|PDF »
Discovery and Scoring of Protein Interaction Subnetworks Discriminative of Late Stage Human Colon Cancer.
R. K. Nibbe, S. Markowitz, L. Myeroff, R. Ewing, and M. R. Chance (2009)
Mol. Cell. Proteomics
8, 827-845
|Abstract »|Full Text »|PDF »
KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
J. J. Yeh, E. D. Routh, T. Rubinas, J. Peacock, T. D. Martin, X. J. Shen, R. S. Sandler, H. J. Kim, T. O. Keku, and C. J. Der (2009)
Mol. Cancer Ther.
8, 834-843
|Abstract »|Full Text »|PDF »
mtDNA mutation pattern in tumors and human evolution are shaped by similar selective constraints.
I. Zhidkov, E. A. Livneh, E. Rubin, and D. Mishmar (2009)
Genome Res.
19, 576-580
|Abstract »|Full Text »|PDF »
A Transposon-Based Genetic Screen in Mice Identifies Genes Altered in Colorectal Cancer.
T. K. Starr, R. Allaei, K. A. T. Silverstein, R. A. Staggs, A. L. Sarver, T. L. Bergemann, M. Gupta, M. G. O'Sullivan, I. Matise, A. J. Dupuy, et al. (2009)
Science
323, 1747-1750
|Abstract »|Full Text »|PDF »
Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers.
K. D. Siegmund, P. Marjoram, Y.-J. Woo, S. Tavare, and D. Shibata (2009)
PNAS
106, 4828-4833
|Abstract »|Full Text »|PDF »
Heterogeneity of the MYCN Oncogene in Neuroblastoma.
J. Theissen, M. Boensch, R. Spitz, D. Betts, S. Stegmaier, H. Christiansen, F. Niggli, F. Schilling, M. Schwab, T. Simon, et al. (2009)
Clin. Cancer Res.
15, 2085-2090
|Abstract »|Full Text »|PDF »
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.
S. Sur, R. Pagliarini, F. Bunz, C. Rago, L. A. Diaz Jr., K. W. Kinzler, B. Vogelstein, and N. Papadopoulos (2009)
PNAS
106, 3964-3969
|Abstract »|Full Text »|PDF »
Mapping DNA structural variation in dogs.
W.-K. Chen, J. D. Swartz, L. J. Rush, and C. E. Alvarez (2009)
Genome Res.
19, 500-509
|Abstract »|Full Text »|PDF »
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.
A. Greenhough, H. J.M. Smartt, A. E. Moore, H. R. Roberts, A. C. Williams, C. Paraskeva, and A. Kaidi (2009)
Carcinogenesis
30, 377-386
|Abstract »|Full Text »|PDF »
Tumor-Induced Suppression of CTL Expansion and Subjugation by gp96-Ig Vaccination.
T. H. Schreiber, V. V. Deyev, J. D. Rosenblatt, and E. R. Podack (2009)
Cancer Res.
69, 2026-2033
|Abstract »|Full Text »|PDF »
5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a Phospholipase D Pharmacological Inhibitor That Alters Cell Spreading and Inhibits Chemotaxis.
W. Su, O. Yeku, S. Olepu, A. Genna, J.-S. Park, H. Ren, G. Du, M. H. Gelb, A. J. Morris, and M. A. Frohman (2009)
Mol. Pharmacol.
75, 437-446
|Abstract »|Full Text »|PDF »
Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screening.
A. B. Bialkowska, Y. Du, H. Fu, and V. W. Yang (2009)
Mol. Cancer Ther.
8, 563-570
|Abstract »|Full Text »|PDF »
A Systems Perspective of Ras Signaling in Cancer.
E. C. Stites and K. S. Ravichandran (2009)
Clin. Cancer Res.
15, 1510-1513
|Abstract »|Full Text »|PDF »
Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line.
Q. Zhao, O. L. Caballero, S. Levy, B. J. Stevenson, C. Iseli, S. J. de Souza, P. A. Galante, D. Busam, M. A. Leversha, K. Chadalavada, et al. (2009)
PNAS
106, 1886-1891
|Abstract »|Full Text »|PDF »
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
Y. Jiang, A. Dunbar, L. P. Gondek, S. Mohan, M. Rataul, C. O'Keefe, M. Sekeres, Y. Saunthararajah, and J. P. Maciejewski (2009)
Blood
113, 1315-1325
|Abstract »|Full Text »|PDF »
Mouse models for the study of colon carcinogenesis.
D. W. Rosenberg, C. Giardina, and T. Tanaka (2009)
Carcinogenesis
30, 183-196
|Abstract »|Full Text »|PDF »
Array-based evolution of DNA aptamers allows modelling of an explicit sequence-fitness landscape.
C. G. Knight, M. Platt, W. Rowe, D. C. Wedge, F. Khan, P. J. R. Day, A. McShea, J. Knowles, and D. B. Kell (2009)
Nucleic Acids Res.
37, e6
|Abstract »|Full Text »|PDF »
Protein Kinase C{zeta} Represses the Interleukin-6 Promoter and Impairs Tumorigenesis In Vivo.
A. S. Galvez, A. Duran, J. F. Linares, P. Pathrose, E. A. Castilla, S. Abu-Baker, M. Leitges, M. T. Diaz-Meco, and J. Moscat (2009)
Mol. Cell. Biol.
29, 104-115
|Abstract »|Full Text »|PDF »
In Vivo/Ex Vivo and In Situ Assays Used in Cancer Research: A Brief Review.
C. J. Richardson, Q. Gao, C. Mitsopoulous, M. Zvelebil, L. H. Pearl, and F. M. G. Pearl (2009)
Nucleic Acids Res.
37, D824-D831
|Abstract »|Full Text »|PDF »
A DNA transposon-based approach to validate oncogenic mutations in the mouse.
Q. Su, H. M. Prosser, L. S. Campos, M. Ortiz, T. Nakamura, M. Warren, A. J. Dupuy, N. A. Jenkins, N. G. Copeland, A. Bradley, et al. (2008)
PNAS
105, 19904-19909
|Abstract »|Full Text »|PDF »
Mutational Inactivation of PTPRD in Glioblastoma Multiforme and Malignant Melanoma.
D. A. Solomon, J.-S. Kim, J. C. Cronin, Z. Sibenaller, T. Ryken, S. A. Rosenberg, H. Ressom, W. Jean, D. Bigner, H. Yan, et al. (2008)
Cancer Res.
68, 10300-10306
|Abstract »|Full Text »|PDF »
Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741.
C. S. Fuchs, R. M. Goldberg, D. J. Sargent, J. A. Meyerhardt, B. M. Wolpin, E. M. Green, H. C. Pitot, and M. Pollak (2008)
Clin. Cancer Res.
14, 8263-8269
|Abstract »|Full Text »|PDF »
Unbiased Screening for Transcriptional Targets of ZKSCAN3 Identifies Integrin {beta}4 and Vascular Endothelial Growth Factor as Downstream Targets.
L. Yang, L. Zhang, Q. Wu, and D. D. Boyd (2008)
J. Biol. Chem.
283, 35295-35304
|Abstract »|Full Text »|PDF »
A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities.
K. S. Garman, C. R. Acharya, E. Edelman, M. Grade, J. Gaedcke, S. Sud, W. Barry, A. M. Diehl, D. Provenzale, G. S. Ginsburg, et al. (2008)
PNAS
105, 19432-19437
|Abstract »|Full Text »|PDF »
Mining the Epigenome for Methylated Genes in Lung Cancer.
Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer.
Y. Nikolsky, E. Sviridov, J. Yao, D. Dosymbekov, V. Ustyansky, V. Kaznacheev, Z. Dezso, L. Mulvey, L. E. Macconaill, W. Winckler, et al. (2008)
Cancer Res.
68, 9532-9540
|Abstract »|Full Text »|PDF »
Identification of Pbx1, a Potential Oncogene, as a Notch3 Target Gene in Ovarian Cancer.
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers.
R. J. Leary, J. C. Lin, J. Cummins, S. Boca, L. D. Wood, D. W. Parsons, S. Jones, T. Sjoblom, B.-H. Park, R. Parsons, et al. (2008)
PNAS
105, 16224-16229
|Abstract »|Full Text »|PDF »
Loss of the Epigenetic Tumor Suppressor SNF5 Leads to Cancer without Genomic Instability.
E. S. McKenna, C. G. Sansam, Y.-J. Cho, H. Greulich, J. A. Evans, C. S. Thom, L. A. Moreau, J. A. Biegel, S. L. Pomeroy, and C. W. M. Roberts (2008)
Mol. Cell. Biol.
28, 6223-6233
|Abstract »|Full Text »|PDF »
The Conflict Between Complex Systems and Reductionism.
A Bicistronic CYCLIN D1-TROP2 mRNA Chimera Demonstrates a Novel Oncogenic Mechanism in Human Cancer.
E. Guerra, M. Trerotola, R. Dell' Arciprete, V. Bonasera, B. Palombo, T. El-Sewedy, T. Ciccimarra, C. Crescenzi, F. Lorenzini, C. Rossi, et al. (2008)
Cancer Res.
68, 8113-8121
|Abstract »|Full Text »|PDF »
Prioritization of candidate cancer genes--an aid to oncogenomic studies.
S. J. Furney, B. Calvo, P. Larranaga, J. A. Lozano, and N. Lopez-Bigas (2008)
Nucleic Acids Res.
36, e115
|Abstract »|Full Text »|PDF »
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses.
S. Jones, X. Zhang, D. W. Parsons, J. C.-H. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, H. Kamiyama, A. Jimeno, et al. (2008)
Science
321, 1801-1806
|Abstract »|Full Text »|PDF »
An Integrated Genomic Analysis of Human Glioblastoma Multiforme.
D. W. Parsons, S. Jones, X. Zhang, J. C.-H. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I-M. Siu, G. L. Gallia, et al. (2008)
Science
321, 1807-1812
|Abstract »|Full Text »|PDF »
Cell type-specific DNA methylation patterns in the human breast.
N. Bloushtain-Qimron, J. Yao, E. L. Snyder, M. Shipitsin, L. L. Campbell, S. A. Mani, M. Hu, H. Chen, V. Ustyansky, J. E. Antosiewicz, et al. (2008)
PNAS
105, 14076-14081
|Abstract »|Full Text »|PDF »
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters.
M. Okabe, G. Szakacs, M. A. Reimers, T. Suzuki, M. D. Hall, T. Abe, J. N. Weinstein, and M. M. Gottesman (2008)
Mol. Cancer Ther.
7, 3081-3091
|Abstract »|Full Text »|PDF »
A Novel Acetylenic Tricyclic bis-(Cyano Enone) Potently Induces Phase 2 Cytoprotective Pathways and Blocks Liver Carcinogenesis Induced by Aflatoxin.
K. Liby, M. M. Yore, B. D. Roebuck, K. J. Baumgartner, T. Honda, C. Sundararajan, H. Yoshizawa, G. W. Gribble, C. R. Williams, R. Risingsong, et al. (2008)
Cancer Res.
68, 6727-6733
|Abstract »|Full Text »|PDF »
Tumorigenic activity and therapeutic inhibition of Rheb GTPase.
K. J. Mavrakis, H. Zhu, R. L.A. Silva, J. R. Mills, J. Teruya-Feldstein, S. W. Lowe, W. Tam, J. Pelletier, and H.-G. Wendel (2008)
Genes & Dev.
22, 2178-2188
|Abstract »|Full Text »|PDF »
A genome-wide RNAi screen for Wnt/{beta}-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer.
W. Tang, M. Dodge, D. Gundapaneni, C. Michnoff, M. Roth, and L. Lum (2008)
PNAS
105, 9697-9702
|Abstract »|Full Text »|PDF »
A comprehensive assay for targeted multiplex amplification of human DNA sequences.
S. Krishnakumar, J. Zheng, J. Wilhelmy, M. Faham, M. Mindrinos, and R. Davis (2008)
PNAS
105, 9296-9301
|Abstract »|Full Text »|PDF »
The Previously Undescribed ZKSCAN3 (ZNF306) Is a Novel "Driver" of Colorectal Cancer Progression.
L. Yang, S. R. Hamilton, A. Sood, T. Kuwai, L. Ellis, A. Sanguino, G. Lopez-Berestein, and D. D. Boyd (2008)
Cancer Res.
68, 4321-4330
|Abstract »|Full Text »|PDF »
BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines.
R. Leboeuf, J. E. Baumgartner, M. Benezra, R. Malaguarnera, D. Solit, C. A. Pratilas, N. Rosen, J. A. Knauf, and J. A. Fagin (2008)
J. Clin. Endocrinol. Metab.
93, 2194-2201
|Abstract »|Full Text »|PDF »
Mechanisms of malignant progression.
R. A. Weinberg (2008)
Carcinogenesis
29, 1092-1095
|Full Text »|PDF »
Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome.
M. O. Hoque, M. S. Kim, K. L. Ostrow, J. Liu, G. B. A. Wisman, H. L. Park, M. L. Poeta, C. Jeronimo, R. Henrique, A. Lendvai, et al. (2008)
Cancer Res.
68, 2661-2670
|Abstract »|Full Text »|PDF »
Comparative lesion sequencing provides insights into tumor evolution.
S. Jones, W.-d. Chen, G. Parmigiani, F. Diehl, N. Beerenwinkel, T. Antal, A. Traulsen, M. A. Nowak, C. Siegel, V. E. Velculescu, et al. (2008)
PNAS
105, 4283-4288
|Abstract »|Full Text »|PDF »
An Oncogene-Induced DNA Damage Model for Cancer Development.
T. D. Halazonetis, V. G. Gorgoulis, and J. Bartek (2008)
Science
319, 1352-1355
|Abstract »|Full Text »|PDF »
Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers.
T. D. Barber, K. McManus, K. W. Y. Yuen, M. Reis, G. Parmigiani, D. Shen, I. Barrett, Y. Nouhi, F. Spencer, S. Markowitz, et al. (2008)
PNAS
105, 3443-3448
|Abstract »|Full Text »|PDF »
Clonal Selection in Malignant Transformation of Human Fibroblasts Transduced with Defined Cellular Oncogenes.
A. M. Mahale, Z. A.T. Khan, M. Igarashi, G. J. Nanjangud, R. F. Qiao, S. Yao, S. W. Lee, and S. A. Aaronson (2008)
Cancer Res.
68, 1417-1426
|Abstract »|Full Text »|PDF »
Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better.
Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.
M. Emaduddin, D. C. Bicknell, W. F. Bodmer, and S. M. Feller (2008)
PNAS
105, 2358-2362
|Abstract »|Full Text »|PDF »
Improving Outcomes for Patients With Hormone Receptor-Positive Breast Cancer: Back to the Drawing Board.
M. J. Ellis (2008)
J Natl Cancer Inst
100, 159-161
|Full Text »|PDF »
Cancer Proliferation Gene Discovery Through Functional Genomics.
M. R. Schlabach, J. Luo, N. L. Solimini, G. Hu, Q. Xu, M. Z. Li, Z. Zhao, A. Smogorzewska, M. E. Sowa, X. L. Ang, et al. (2008)
Science
319, 620-624
|Abstract »|Full Text »|PDF »